ELDN vs ELTX

Eledon Pharmaceuticals, Inc. vs Elicio Therapeutics, Inc. — Valuation Comparison 2026

ELDN

Biotechnology
Eledon Pharmaceuticals, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$3.87
Last close
Models
7/13
Active
VS

ELTX

Biotechnology
Elicio Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$10.61
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ELDN Fair ValueELDN Upside ELTX Fair ValueELTX Upside
Bayesian DCF Intrinsic $1.08 -72.1% $2.98 -71.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.11 -97.0% $5.01 -52.7%
Dynamic NAV Asset-Based $1.25 -67.7% $0.32 -97.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELDN vs ELTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELDN vs ELTX — Which Stock Is More Undervalued?

ELTX scores higher with a 4.1/10 quality rating vs ELDN's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Eledon Pharmaceuticals, Inc. (ELDN) and Elicio Therapeutics, Inc. (ELTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELDN currently trades at $3.87 with a QOC of 3.9/10, while ELTX trades at $10.61 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).